Interstitial irradiation of a large, low grade ependymoma with stereotactically implanted Iodine-125 seeds

1993 ◽  
Vol 122 (1-2) ◽  
pp. 127-129 ◽  
Author(s):  
J. Voges ◽  
C. Gaus ◽  
W. Schlegel ◽  
O. Pastyr ◽  
B. Wowra ◽  
...  
Keyword(s):  
Low Grade ◽  
Interstitial Irradiation ◽  
Iodine 125

scholarly journals Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Indrawati Hadi ◽  
Daniel Reitz ◽  
Raphael Bodensohn ◽  
Olarn Roengvoraphoj ◽  
Stefanie Lietke ◽  
...  
Keyword(s):  
Risk Factors ◽  
Radiation Necrosis ◽  
Irradiation Time ◽  
External Beam Radiotherapy ◽  
High Grade Glioma ◽  
Metabolic Imaging ◽  
Time Interval ◽  
Low Grade ◽  
External Beam ◽  
Iodine 125

Abstract Purpose Frequency and risk profile of radiation necrosis (RN) in patients with glioma undergoing either upfront stereotactic brachytherapy (SBT) and additional salvage external beam radiotherapy (EBRT) after tumor recurrence or vice versa remains unknown. Methods Patients with glioma treated with low-activity temporary iodine-125 SBT at the University of Munich between 1999 and 2016 who had either additional upfront or salvage EBRT were included. Biologically effective doses (BED) were calculated. RN was diagnosed using stereotactic biopsy and/or metabolic imaging. The rate of RN was estimated with the Kaplan Meier method. Risk factors were obtained from logistic regression models. Results Eighty-six patients (49 male, 37 female, median age 47 years) were included. 38 patients suffered from low-grade and 48 from high-grade glioma. Median follow-up was 15 months after second treatment. Fifty-eight patients received upfront EBRT (median total dose: 60 Gy), and 28 upfront SBT (median reference dose: 54 Gy, median dose rate: 10.0 cGy/h). Median time interval between treatments was 19 months. RN was diagnosed in 8/75 patients. The 1- and 2-year risk of RN was 5.1% and 11.7%, respectively. Tumor volume and irradiation time of SBT, number of implanted seeds, and salvage EBRT were risk factors for RN. Neither of the BED values nor the time interval between both treatments gained prognostic influence. Conclusion The combination of upfront EBRT and salvage SBT or vice versa is feasible for glioma patients. The risk of RN is mainly determined by the treatment volume but not by the interval between therapies.

Image Fusion Analysis of Volumetric Changes after Interstitial Low-Dose-Rate Iodine-125 Irradiation of Supratentorial Low-Grade Gliomas

2007 ◽  
Vol 167 (4) ◽  
pp. 438-444 ◽  
Author(s):  
Jenő Julow ◽  
Tibor Major ◽  
László Mangel ◽  
Gábor Bajzik ◽  
Arpad Viola
Keyword(s):  
Image Fusion ◽  
Dose Rate ◽  
Low Dose ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Low Dose Rate ◽  
Iodine 125 ◽  
Fusion Analysis

Local control of recurrent clival and sacral chordoma after interstitial irradiation with iodine-125

Neurosurgery ◽  
1988 ◽  
Vol 22 (3) ◽  
pp. 479???83 ◽  
Author(s):  
P P Kumar ◽  
R R Good ◽  
F M Skultety ◽  
L G Leibrock
Keyword(s):  
Local Control ◽  
Interstitial Irradiation ◽  
Sacral Chordoma ◽  
Iodine 125

Long-Term Results of Brachytherapy With Temporary Iodine-125 Seeds in Children With Low-Grade Gliomas

2011 ◽  
Vol 79 (4) ◽  
pp. 1131-1138 ◽  
Author(s):  
Rudolf Korinthenberg ◽  
Daniela Neuburger ◽  
Michael Trippel ◽  
Christoph Ostertag ◽  
Guido Nikkhah
Keyword(s):  
Long Term Results ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Iodine 125

scholarly journals Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Juliana Watson ◽  
Alexander Romagna ◽  
Hendrik Ballhausen ◽  
Maximilian Niyazi ◽  
Stefanie Lietke ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Low Grade ◽  
Toxicity Profile ◽  
Who Grade ◽  
Low Grade Gliomas ◽  
Stereotactic Brachytherapy ◽  
Grade Ii ◽  
Iodine 125

Abstract Background This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. Methods This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. Results For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1–5), and a median total implanted activity of 21.8 mCi (range 4.2–43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). Conclusion SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas.

Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy

1996 ◽  
Vol 23 (5) ◽  
pp. 583-586 ◽  
Author(s):  
M. Würker ◽  
K. Herholz ◽  
J. Voges ◽  
U. Pietrzyk ◽  
H. Treuer ◽  
...  
Keyword(s):  
Glucose Consumption ◽  
Low Grade ◽  
Low Grade Gliomas ◽  
Methionine Uptake ◽  
Iodine 125
Sign in / Sign up

Export Citation Format

Share Document